CONTEXT: Medullary thyroid carcinoma (MTC), a tumor of the parafollicular C cells of the gland, comprises 3-5% of all malignant thyroid neoplasms. Calcitonin, a polypeptidic hormone secreted by the neoplastic cells, is considered a very sensitive and specific MTC tumor marker. Patients with MTC usually present elevated serum calcitonin levels, which correlate with tumor burden and prognosis. OBJECTIVES: To describe a case of advanced MTC with normal serum calcitonin and review the literature on this subject. DESIGN: A case study was performed. INTERVENTION: There were no interventions. PATIENTS: A case of advanced MTC with normal serum calcitonin was studied. RESULTS: Serum calcitonin was measured by two distinct assays, a chemiluminescent immunometric and an in-house two-site monoclonal antibody-based immunofluorometric assay. To rule out a "hook effect," or posttranslational modifications of calcitonin molecule, serum dilutions and tumor immunohistochemistry for calcitonin with the same antibodies used for serum calcitonin measurements were performed. Serum calcitonin levels were within the normal range in both assays, whereas the tumor stained strongly positive for calcitonin. These findings suggest that the tumor was able to produce but not to secrete the calcitonin protein. Five other cases of advanced MTC with normal serum calcitonin levels had been previously reported. CONCLUSIONS: We present an unusual case of advanced MTC with normal serum calcitonin levels. Awareness of MTC cases presenting with normal serum calcitonin levels is important in clinical practice and is particularly relevant to centers that use this test for screening.
CONTEXT: Medullary thyroid carcinoma (MTC), a tumor of the parafollicular C cells of the gland, comprises 3-5% of all malignant thyroid neoplasms. Calcitonin, a polypeptidic hormone secreted by the neoplastic cells, is considered a very sensitive and specific MTC tumor marker. Patients with MTC usually present elevated serum calcitonin levels, which correlate with tumor burden and prognosis. OBJECTIVES: To describe a case of advanced MTC with normal serum calcitonin and review the literature on this subject. DESIGN: A case study was performed. INTERVENTION: There were no interventions. PATIENTS: A case of advanced MTC with normal serum calcitonin was studied. RESULTS: Serum calcitonin was measured by two distinct assays, a chemiluminescent immunometric and an in-house two-site monoclonal antibody-based immunofluorometric assay. To rule out a "hook effect," or posttranslational modifications of calcitonin molecule, serum dilutions and tumor immunohistochemistry for calcitonin with the same antibodies used for serum calcitonin measurements were performed. Serum calcitonin levels were within the normal range in both assays, whereas the tumor stained strongly positive for calcitonin. These findings suggest that the tumor was able to produce but not to secrete the calcitonin protein. Five other cases of advanced MTC with normal serum calcitonin levels had been previously reported. CONCLUSIONS: We present an unusual case of advanced MTC with normal serum calcitonin levels. Awareness of MTC cases presenting with normal serum calcitonin levels is important in clinical practice and is particularly relevant to centers that use this test for screening.
Authors: Allen S Ho; Lu Wang; Frank L Palmer; Changhong Yu; Arnbjorn Toset; Snehal Patel; Michael W Kattan; R Michael Tuttle; Ian Ganly Journal: Ann Surg Oncol Date: 2014-11-04 Impact factor: 5.344
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: Daisy V Alapat; Kenneth B Ain; David A Sloan; Kristin G Monaghan; Rouzan G Karabakhtsian Journal: Endocrine Date: 2011-01-18 Impact factor: 3.633